Menactra Needs Long-Term Safety, Efficacy Studies Post-Approval – Cmte.
Executive Summary
Sanofi-Aventis should commit to long-term efficacy and safety post-approval studies for its quadravalent meningococcal conjugate vaccine Menactra (MCV-4), an FDA advisory committee said
You may also be interested in...
Sanofi-Aventis Menactra Approved; Launch Awaits ACIP Recommendations
Sanofi-Aventis' launch of its meningococcal conjugate vaccine Menactra will await formal recommendations for use by the Centers for Disease Control & Prevention's Advisory Committee on Immunization Practices next month
Sanofi-Aventis Menactra Approved; Launch Awaits ACIP Recommendations
Sanofi-Aventis' launch of its meningococcal conjugate vaccine Menactra will await formal recommendations for use by the Centers for Disease Control & Prevention's Advisory Committee on Immunization Practices next month
Sanofi-Aventis Menactra Market Is $3.5 Bil. Over 10 Years, CDC Says
The potential market for Sanofi-Aventis' meningococcal conjugate vaccine Menactra is $3.5 bil. over 10 years, a Centers for Disease Control & Prevention analysis indicates